Target approach to treating osseous system pathology
https://doi.org/10.17650/1994-4098-2010-0-4-43-48
Abstract
ВTo maintain the normal status of the osseous system in cancer patients is an important task of practical oncology as the complications associated with skeletal pathology substantially worsen quality of life in the patients, increase the cost of treatment, and can affect their lifespan. Osseous complications must be prevented not only in patients with skeletal metastatic lesion, but also in healthy individuals cured from cancer, who may have a significant reduction in bone density (osteoporosis) as a complication due to antitumor therapy. Along with bisphosphonates that are well-known and traditionally used in this situation, there have today been target drugs (denosumab) that can be effective in monitoring the osseous system and preventing the complications of osteoporosis and skeletal metastatic lesion.
About the Authors
M. B. Stenina
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. D. Petrova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Hortobagyi G.N. Systemic therapy for bone metastasis: past, present and future. Educational Book Articles. ASCO, 2010; p. 3–7.
2. Roodman G.D. Mechanisms of disease: mechanisms of bone metastasis. New Engl J Med 2004;16:1655–64.
3. Body J.J., Greipp P., Coleman R.E. et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97(Suppl):887–92.
4. Boyle W.J., Simonet W.S., Lacey D.L. et al. Osteoclast differentiation and activation. Nature 2003;423:337–42.
5. George S., Brenner A., Sarantopoulos J. et al. RANK Ligand: effects of inhibition. Curr Oncol Rep 2010;12:80–6.
6. Lipton A., Steger G.G., Figueroa J. et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431–7.
7. Stopeck A., De Boer R., Fujiwara Y. et al. A comparison of denosumab versus zoledronic acid for the prevention of skeletal-related events in breast cancer patients with bone metastases [abstract 22]. Cancer Res 2009;69 (Suppl 1):490.
8. Lipton A., Stopeck A., von Moos R.A. Meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases. J Clin Oncol 2010;28 (Suppl):15.
9. Abstr 9015.
10. Ellis G.K., Bone H.G., Chlebowski R. et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875–82.
11. Cummings S.R., Martin J.S., McClung M.R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. New Engl J Med 2009;361:756–65.
12. Smith M.R., Egerdie B., Toriz N.H. et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. New Engl J Med 2009;361:745–55.
13. Gauthier J.Y., Chauret N., Cromlish W. et al. The discovery of odanacatib (MK- 0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Letters 2008;18:923–8.
14. Harms J.F., Welch D.R., Samant R.S. et al. A small molecule antagonist of the alpha (v) beta-3 integrin suppresses MDA- MB-435 skeletal metastasis. Clin Exp Metastas 2004;21:119–28.
15. Murphy M.G., Cerchio K., Stoch S.A. et al. Effect of L-000845704, an alpha-V- beta-3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005;90:2022–8.
Review
For citations:
Stenina M.B., Petrova A.D. Target approach to treating osseous system pathology. Tumors of female reproductive system. 2010;(4):43-48. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-4-43-48
Views:
464
Email this article 